Hepatocellular carcinoma is a primary liver malignancy in which the risk of development is always multifunctional. Interleukin-6 is a proinflammatory and multifunctional cytokine, which plays an important role in the immune response, haematopoiesis and defence against viral infection. We aimed to evaluate the frequency of Interleukin-6 mutations (rs2069837 and rs17147230) associated with genetic risk of hepatocellular carcinoma in Khyber Pakthunkhwa population. A total of 72 hepatocellular carcinoma cases and 38 controls were included in this study. The genomic DNA was extracted from the peripheral blood cells and Interleukin-6 genotyping was performed using T-ARMS-PCR technique. Our results show a significant increase risk of developing hepatocellular carcinoma with the mutation within Interleukin-6 gene with heterozygous G allele (rs2069837) (OR = 10.667, 95%CI = 3.923–29.001, p = < 0.0001) and heterozygous T allele (rs17147230) (OR = 75.385, 95%CI = 9.797–580.065, p = < 0.0001). However, under recessive gene model the results were insignificant in case of Interleukin-6 rs2069837 (OR = 0.605, 95%CI = 0.217–1.689, p = 0.337), while significant in case of Interleukin-6 rs17147230 (OR = 0.298, 95%CI = 0.121–0.734, p = 0.0085). In conclusion, Interleukin-6 mutation is associated with hepatocellular carcinoma susceptibility. More related studies with other associated interleukins and their whole gene sequencing will be required.

中文翻译：

---

HCV慢性感染的HCC患者的白细胞介素6多态性

肝细胞癌是一种原发性肝脏恶性肿瘤，其发展风险始终是多功能的。Interleukin-6 是一种促炎性多功能细胞因子，在免疫反应、造血和防御病毒感染中发挥重要作用。我们的目的是评估与开伯尔省人口肝细胞癌遗传风险相关的白细胞介素 6 突变（rs2069837 和 rs17147230）的频率。本研究共纳入 72 例肝细胞癌病例和 38 例对照。从外周血细胞中提取基因组DNA并使用T-ARMS-PCR技术进行白细胞介素6基因分型。我们的研究结果显示，白细胞介素 6 基因内突变与杂合 G 等位基因 (rs2069837)（OR = 10.667，95%CI = 3.923–29.001，p = < 0.0001）和杂合 T 等位基因（rs207 ) (OR = 75.385, 95% CI = 9.797–580.065, p = < 0.0001)。然而，在隐性基因模型下，Interleukin-6 rs2069837 的结果不显着（OR = 0.605, 95%CI = 0.217–1.689, p = 0.337），而在 Interleukin-6 rs17147230 的情况下显着（OR = 9529）。 %CI = 0.121–0.734，p = 0.0085）。总之，白细胞介素6突变与肝细胞癌易感性有关。需要对其他相关白介素及其全基因测序进行更多相关研究。0001) 和杂合 T 等位基因 (rs17147230)（OR = 75.385，95%CI = 9.797–580.065，p = < 0.0001）。然而，在隐性基因模型下，Interleukin-6 rs2069837 的结果不显着（OR = 0.605, 95%CI = 0.217–1.689, p = 0.337），而在 Interleukin-6 rs17147230 的情况下显着（OR = 9529）。 %CI = 0.121–0.734，p = 0.0085）。总之，白细胞介素6突变与肝细胞癌易感性有关。需要对其他相关白介素及其全基因测序进行更多相关研究。0001) 和杂合 T 等位基因 (rs17147230)（OR = 75.385，95%CI = 9.797–580.065，p = < 0.0001）。然而，在隐性基因模型下，Interleukin-6 rs2069837 的结果不显着（OR = 0.605, 95%CI = 0.217–1.689, p = 0.337），而在 Interleukin-6 rs17147230 的情况下显着（OR = 9529）。 %CI = 0.121–0.734，p = 0.0085）。总之，白细胞介素6突变与肝细胞癌易感性有关。需要对其他相关白介素及其全基因测序进行更多相关研究。总之，白细胞介素6突变与肝细胞癌易感性有关。需要对其他相关白介素及其全基因测序进行更多相关研究。总之，白细胞介素6突变与肝细胞癌易感性有关。需要对其他相关白介素及其全基因测序进行更多相关研究。